New diabetes shot aims to help when pills or insulin fall short
NCT ID NCT07387003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new injectable medicine, GZR101-80, for people with type 2 diabetes that is not well controlled by current pills or basal insulin. About 345 adults will receive the drug for 16 weeks to see if it lowers blood sugar and HbA1c safely. The goal is better daily control, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gan & Lee Pharmaceuticals
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection outperform semaglutide for diabetes remission?
- Can a drop of blood predict disease years before it strikes?
- Fatty liver may be a hidden driver of heart attacks in diabetes
- Could date seed powder help tame type 2 diabetes?
- Triple-Drug combo aims to improve diabetes control and weight loss
- Could a wearable sensor transform early diabetes care?